Avoro Capital Advisors LLC
Q2 2021 13F-HR Holdings
Net value change ($000)
-41,776
(-0.7%)
New positions
5
Sold out positions
7
Turnover %
14.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ASND | 249,945 | NEW |
| ALNY | 169,520 | NEW |
| GLUE | 62,153 | NEW |
| CONSTELLATION PHARMACEUTICALS INC | 39,497 | 57.2% |
| UTHR | 36,420 | 7.3% |
| ARGX | 30,090 | 11.8% |
| SRPT | 26,336 | 16.4% |
| APLS | 20,621 | 48.1% |
| MNKD | 17,634 | 60.0% |
| Horizon Therapeutics Public Ltd Co | 14,400 | 1.7% |
Top Reduces (Value $000, Stocks/ETFs)
| ASCENDIS PHARMA | -244,872 | -100.0% |
| VRTX | -141,558 | -47.1% |
| ADVM | -54,555 | -69.2% |
| TVTX | -31,188 | -100.0% |
| XLRN | -30,360 | -7.5% |
| MDGL | -27,873 | -16.7% |
| KURA | -26,761 | -23.7% |
| RLMD | -23,766 | -44.3% |
| PRAX | -18,193 | -38.3% |
| Mersana Therapeutics, Inc. | -17,680 | -16.1% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
4,785
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|